The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug

Advertisement
The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug
Atthapon Raksthaput/Shutterstock

Hello,

Advertisement

Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...



Here are the 9 biggest biotech winners after the FDA took an entirely new approach to approve Biogen's Alzheimer's drug

  • A historic approval of Biogen's Alzheimer's drug will have ramifications across the drug industry.
  • Analysts expect Aduhelm's launch to spur more investor interest in Alzheimer's research.

Here are the nine companies that stand to benefit the most>>


The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug
General Atlantic managing director Robb VorhoffGeneral Atlantic

Why General Atlantic's top healthcare dealmaker is betting on telemedicine sticking around long after the pandemic subsides

Read more from the interview here>>

Advertisement


The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug
Brian Ach/Getty Images for TechCrunch

Clover Health gained more than 80% as WallStreetBets fueled the meme-stock rally

Here's what happened>>


More stories we're reading:


- Lydia

{{}}